The Footnote

THE CHEMO FOOT: A PODIATRIC GUIDE TO ASSESSING AND MANAGING FOOT & ANKLE TOXICITIES IN PATIENTS UNDERGOING CANCER THERAPY

Author attribution not recorded

A footprint dissolving into sand with a central solid core, representing the fragile mobility of cancer patients.

By Steven Gillingham

Introduction

Cancer treatment is a triumph of modern medicine, yet it remains one of the most physically punishing experiences a human body can endure. Chemotherapy, immunotherapy, targeted agents and combination regimens are designed to disrupt malignant biology, but they also disturb every rapidly dividing, hormonally active or neurologically sensitive tissue they touch. The feet, those durable, load-bearing, friction-exposed structures sit at the crossroads of vascular, neural, dermatological, and mechanical stress. Unsurprisingly, they bear a disproportionate burden of toxicity.

Despite this, foot and ankle complications occupy little space in oncology guidelines and often even less in routine clinical care. Patients frequently report peeling soles, numb toes, throbbing heels, lifting nails, stabbing neuropathic pain or burning redness they cannot stand on, yet these concerns are rarely escalated beyond symptomatic reassurance. The result is avoidable suffering, preventable infection, unnecessary chemotherapy dose reductions, and functional decline at a time when patients urgently need mobility and independence.

Chemotherapy-induced peripheral neuropathy (CIPN), palmar–plantar erythrodysesthesia (also known as hand–foot syndrome or PPE), nail toxicity, xerosis, fissuring, blistering, and reduced healing capacity are all well-documented adverse effects that disrupt quality of life and can impair cancer therapy adherence.(1–4) Small lesions that would normally resolve uneventfully may worsen rapidly in immunosuppressed or neutropenic patients, sometimes requiring hospitalisation.(5) Altered gait patterns from neuropathy increase falls risk, which further elevates morbidity and emergency presentations.(6) For many patients, the feet are not simply collateral damage, they are the tipping point between tolerating treatment and abandoning it.

This feature explores the mechanisms by which chemotherapy and related cancer therapies impact the feet, provides a rigorous yet practical clinical workup tailored specifically for podiatric settings, and outlines evidence-based management strategies that can keep patients mobile, safe, and on track with their oncology treatment plans. It is written to reflect real-world podiatric practice, grounded in established oncology and dermatology literature, integrating the mechanical realities of the foot with the systemic effects of cancer therapy.

Pathophysiology of Chemotherapy-Induced Foot and Ankle Toxicity

Disruption of keratinocyte turnover and plantar barrier function

Many chemotherapeutic agents target rapidly dividing cells. Unfortunately, keratinocytes in the epidermis and eccrine structures of the soles are among the fastest-turnover cells in the body. Agents including capecitabine, 5-fluorouracil, doxorubicin, and taxanes interfere with DNA synthesis or microtubule function, leading to thinning of the epidermis, dysregulated keratinocyte maturation, and impaired barrier repair.(7–9) The consequence is an epidermis that becomes brittle, desiccated, and prone to peeling, erythema, and fissuring, particularly in regions exposed to repetitive shear stress such as the heels, forefoot and toe creases.

Palmar–plantar erythrodysesthesia (PPE) emerges from a combination of dermal inflammation, drug leakage into eccrine sweat glands, and microvascular damage.(10) The condition frequently limits ambulation, increases tenderness under pressure points, and in severe cases can cause blistering or functional inability to bear weight.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN is among the most clinically impactful adverse events of chemotherapy, particularly with platinum agents (cisplatin, oxaliplatin, carboplatin), taxanes, vinca alkaloids and proteasome inhibitors such as bortezomib. (11,12) Its mechanisms include axonal degeneration, mitochondrial dysfunction, disruption of microtubular transport, and direct toxicity to dorsal root ganglia.(13)

Symptoms typically begin distally in a “stocking–glove” distribution. For podiatry, the key problems include:

  • Loss of protective sensation

  • Burning, tingling or lancinating pain

  • Proprioceptive impairment

  • Ataxic gait

  • Altered foot loading patterns

  • Intrinsic foot muscle weakness

  • Increased fall risk

A systematic review by Seretny et al. estimated the prevalence of CIPN to be 68% within the first month of chemotherapy and approximately 30% at six months after completion.(14) These changes significantly alter biomechanics, increase plantar pressures, and predispose to ulcers, especially when coupled with immunosuppression.

Microvascular fragility and impaired healing

Chemotherapy affects endothelial integrity and the inflammatory cascade, leading to capillary fragility and impaired wound healing.(15) Small shear injuries on the plantar surface may progress more rapidly than expected, particularly in patients who are neutropenic or anaemic. Thrombocytopenia further increases bleeding risk from minor foot trauma, while corticosteroids used as antiemetics or premedication contribute to dermal thinning and atrophy.

Nail matrix toxicity

Nail changes reflect injury to the matrix, nail bed, periungual tissues or microvasculature. Taxanes and anthracyclines are most frequently implicated in onycholysis, subungual haemorrhage, onychomadesis and paronychia.(16) EGFR inhibitors and tyrosine kinase inhibitors can cause pronounced periungual inflammation.(17)

These presentations are not merely cosmetic: nail detachment exposes the nail bed to infection, increases pain, and alters toe biomechanics. Many patients spontaneously offload painful nails, inadvertently changing gait mechanics.

Gait changes from systemic illness

Fatigue, anaemia, corticosteroid myopathy, cachexia, and reduced proprioception collectively impair mobility. Patients often adopt wider stances or shortened strides to compensate for neuropathy or pain, increasing lateral loading and forefoot strain patterns.(18) These gait alterations may be subtle yet clinically important.

Clinical Workup: A Comprehensive Podiatric Assessment for Patients on Chemotherapy

A meticulous assessment is essential because subtle changes may herald serious complications. The following framework aligns with oncology toxicity grading systems while being tailored to podiatric examination.

History

A detailed history begins with understanding the cancer itself: the primary tumour, stage, and current treatment regimen. Specific chemotherapeutic agents carry predictable toxicity profiles, and patients on combination regimens may experience overlapping effects. It is important to establish the number of cycles completed, the timing of the most recent infusion, and any known toxicity already documented by the oncology team. Agents such as capecitabine, for example, peak in PPE incidence after several cycles, while taxane-induced neuropathy can begin after only one or two treatments.(19)

Functional concerns should be explored in the patient’s own language. Many will describe walking "on marbles," "on sandpaper," or "like my feet are asleep." Others note difficulty with stairs, new clumsiness, inability to tolerate certain shoes, or increased foot pain during treatment weeks. These narratives often provide better clinical insight than formal neurological scores.

The medical history should also include comorbidities such as diabetes, peripheral vascular disease, autoimmune disease, or prior neuropathy, all of which may worsen chemotherapy toxicity. Medications such as corticosteroids or aromatase inhibitors can contribute to musculoskeletal issues, while neutropenia, thrombocytopenia, and anaemia directly influence foot safety.

Dermatological Examination

A full skin inspection includes the soles, interdigital spaces, dorsal foot, and periungual tissues. Features to document include erythema, desquamation, thickening, blistering, fissuring, or areas of tenderness indicative of emerging PPE. The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) can be adapted to grade PPE severity, which is useful when communicating findings to oncology teams.(20)

Peeling heels, superficial cracking, or diffuse xerosis can be early indicators of barrier dysfunction. In high-risk patients, even minor fissures warrant proactive management. In immunosuppressed patients, the threshold for concern is lower; superficial fungal infections, mild erythema, or small erosions can progress rapidly.

Nail Assessment

Nail examination focuses on identifying onycholysis, paronychia, subungual bleeding, or signs of infection. Taxane-related onycholysis often begins distally and progresses proximally, while EGFR inhibitor-induced paronychia typically manifests as painful periungual erythema with or without granulation tissue.(17) Painful nails may cause gait deviation, which in turn creates new pressure points, especially under the lateral forefoot.

Neurological Assessment

Neurological testing includes monofilament sensation, light touch, vibration, pinprick and proprioception, but equal emphasis should be placed on assessing functional balance. A patient with mild sensory loss may already demonstrate significant gait instability. Observing tandem walking, Romberg testing, heel and toe walking, and general foot intrinsic strength can reveal early deficits not captured by sensory testing alone.

Loss of proprioception is common in CIPN and is associated with falls.(6) Video gait analysis can be particularly helpful in documenting evolving patterns, such as lateral drift or reduced push-off.

Vascular Examination

Standard vascular assessment includes palpation of pedal pulses, capillary refill, skin temperature, and colour changes. Chemotherapy-induced endothelial dysfunction may cause cold feet, mottling or slow healing, although these findings must be interpreted in the context of overall health. Lymphoedema is common in patients with breast, gynaecological or melanoma treatments and increases the risk of infection in the distal limb.

Musculoskeletal and Gait Evaluation

The musculoskeletal examination assesses joint range of motion, intrinsic foot muscle strength, calf flexibility, and structural deformities such as hallux valgus or cavus foot types that can exacerbate pressure under toxic conditions. Gait analysis must consider footwear: patients often switch to soft slippers or loose shoes to reduce pain, inadvertently worsening instability.

Risk Stratification

A risk-based follow-up plan acknowledges that patients with neuropathy, fissures, nail loss, PPE or immunosuppression are at higher risk of serious complications. High-risk patients benefit from frequent monitoring to prevent progression to infection or ulceration.

MANAGEMENT & TREATMENT

Management Principles in Chemotherapy-Related Foot and Ankle Toxicity

Managing the feet of patients undergoing chemotherapy requires a combination of dermatological expertise, neurological insight, mechanical intervention, and an appreciation of the broader oncological context. Unlike typical podiatric presentations, the threshold for concern is lower, the pace of deterioration is faster, and the consequences of missed pathology are magnified by immunosuppression, thrombocytopenia, and impaired healing. Effective management therefore blends clinical vigilance with practical simplicity: protecting skin, stabilising gait, preserving nails, preventing infection, and maintaining the patient’s capacity to walk throughout therapy.

A central objective is to preserve continuity of oncology treatment. Severe palmar–plantar erythrodysesthesia (PPE) or worsening neuropathy are frequent reasons for chemotherapy dose reductions or delays.(21) By intercepting early dermatological or neurological changes, podiatric care can reduce the risk of functional decline and contribute directly to maintaining treatment adherence.

Skin Management

Xerosis, Peeling, and Barrier Dysfunction

Xerosis is one of the most common dermatological toxicities of chemotherapy, particularly with antimetabolites and targeted therapies.(8) The soles become dry, flaky, and tender, often peeling in sheets. The primary goal is the restoration of the epidermal barrier. Urea-containing moisturisers (10–25%) have been shown to improve hydration and reduce fissuring by enhancing water-binding capacity and promoting gentle keratolysis.(22) Lactic acid preparations and ceramide-based formulations also support barrier repair, although fragrance-free, non-irritating products are essential in patients with inflamed skin.

Emollients should be applied twice daily, and patients should be encouraged to use socks overnight to enhance absorption. Where peeling is extensive, soft occlusion may reduce transepidermal water loss, although active blistering or erythema should be approached cautiously to avoid trapping moisture in inflamed tissue. Conservative debridement of loose skin is appropriate, but aggressive removal of callus or hyperkeratosis should be avoided during periods of neutropenia or in the presence of PPE, where the skin is already structurally compromised.

Heel Fissures

Heel fissures develop readily in chemotherapy patients due to the combination of xerosis, epidermal thinning, and altered weight-bearing mechanics. These may be painful and act as portals of entry for bacteria. Treatment includes conservative removal of thick keratin, followed by urea 25–40% creams to soften and hydrate the surrounding skin. Silipos or gel heel sleeves can redistribute shear force and provide occlusion to enhance healing. In patients with neutropenia, even small fissures warrant prophylactic antiseptic measures to reduce infection risk.(5)

Palmar–Plantar Erythrodysesthesia (Hand–Foot Syndrome)

PPE is most strongly associated with capecitabine, 5-FU, liposomal doxorubicin, and some targeted agents. Clinical manifestations range from mild erythema and dysesthesia to severe blistering, ulceration, and functional disability.(10)

Management is severity-based:

  • Mild PPE involves tenderness, minimal erythema, and mild desquamation. Cooling strategies such as gel socks or cool water immersion can reduce discomfort. Emollients, keratolytics, and reducing friction through footwear modifications are effective supportive interventions.

  • Moderate PPE is characterised by increased pain, more extensive redness, and functional limitation. Topical corticosteroids have shown benefit in reducing inflammation when used under oncological guidance.(23) Pressure redistribution is critical: orthoses, gel insoles, soft EVA footbeds, and cushioned footwear help reduce mechanical loading on painful areas.

  • Severe PPE often requires oncological dose reduction or temporary cessation of chemotherapy, as recommended in ASCO and ESMO guidelines.(20,24) Podiatric care focuses on wound protection, blister care, infection surveillance, and urgent communication with the oncology team.

Avoidance of heat, tight footwear, prolonged walking, and high-friction activities is essential at all PPE grades, reflecting the inflammatory and mechanical components of the condition.

Nail Toxicity Management

Chemotherapy-related nail changes arise from toxicity to the nail matrix, vascular supply, or periungual structures. Onycholysis, onychomadesis, subungual haemorrhage, and paronychia are common with taxanes, anthracyclines, and EGFR inhibitors.(16,17)

Onycholysis

Taxane-induced onycholysis typically begins at the distal free edge and progresses proximally. The detached plate exposes the nail bed to secondary infection and can become painful under pressure. Management focuses on:

  • Keeping the nail short and smooth to reduce leverage and trauma

  • Gently trimming detached sections

  • Using antiseptic soaks (e.g., diluted chlorhexidine)

  • Applying protective dressings over exposed nail bed

Ultraviolet protection of the nails may also reduce phototoxic damage in certain drug regimens.(16) Patients should be advised to avoid nail salons, acrylic nails, and aggressive filing.

Paronychia

Paronychia associated with EGFR inhibitors tends to be inflammatory, painful, and chronic. The periungual skin becomes tender and may develop granulation tissue. Treatment strategies include warm water soaks, topical antiseptics, silver-impregnated dressings, and topical antibiotics such as mupirocin.(25) In some cases, dilute bleach soaks have demonstrated benefit, although caution is necessary in patients with open fissures or ulceration.(26) Surgical procedures should be avoided unless absolutely necessary and should never be performed during neutropenic periods.

Onychomadesis and Nail Loss

Onychomadesis involves proximal separation of the nail plate and eventual shedding. Once a nail detaches, the priority is protecting the nail bed with non-adherent dressings and ensuring that footwear minimises trauma. Regrowth may take months and may remain dystrophic.

Neuropathy and Gait Management

CIPN is a major determinant of functional impairment in chemotherapy patients and is a primary predictor of falls.(6,11) Management involves both symptomatic relief and biomechanical correction.

Sensory Loss and Proprioceptive Dysfunction

Loss of protective sensation increases the risk of unnoticed injuries. Daily inspection of the feet should be strongly emphasised, mirroring diabetic foot care principles. Patients should avoid walking barefoot, especially on hard or heated surfaces.

Footwear plays a critical role: cushioned shoes with a stable heel counter, wide toe box, and low heel drop provide stability while minimising pressure points. Inserts that enhance proprioceptive feedback such as textured insoles or orthoses with mild medial–lateral posting can help maintain balance.

Neuropathic Pain

Pharmacological treatment for CIPN-related neuropathic pain is typically guided by oncology or general practice. Duloxetine has the strongest evidence for treating CIPN pain, supported by randomised controlled trials and recommended in ASCO guidelines.(27) Gabapentinoids may offer benefit, although evidence is less consistent.

From a podiatric perspective, non-pharmacological interventions include:

  • Avoiding temperature extremes

  • Using cooling socks intermittently

  • Wearing protective, cushioned footwear

  • Using softer insoles to reduce impact during gait

Gait Instability

Gait disturbances arise from a combination of sensory neuropathy, intrinsic muscle weakness, fatigue, and altered biomechanics. Patients may adopt a wider base of support, reduce push-off, and favour midfoot striking to avoid painful areas.

Podiatric interventions include:

  • Proprioceptive-enhancing orthoses

  • EVA footbeds to reduce impact loading

  • Heel cups for stability

  • Teaching simple balance exercises (single-leg stance, tandem stance)

  • Referral to physiotherapy for high-risk patients

Falls history should be documented. Any new or worsening imbalance, especially if sudden, requires medical review to rule out central neurological causes or severe CIPN progression.

Infection Management in Immunosuppressed Patients

Immunosuppression is one of the most critical considerations in the podiatric management of chemotherapy patients. Neutropenia increases susceptibility to bacterial and fungal infections, and minor lesions can deteriorate rapidly.(5)

Fungal Infections

Tinea pedis or onychomycosis is common and may exacerbate fissuring or secondary bacterial infection. Topical antifungals such as terbinafine cream are generally safe and effective, but systemic antifungals should only be used in consultation with oncology due to potential hepatotoxicity and drug interactions.(28)

Bacterial Infections

Redness, swelling, tenderness, warmth, or discharge should prompt immediate escalation. Febrile patients require urgent medical assessment. Cellulitis in a neutropenic patient is a medical emergency. Podiatrists should maintain a low threshold for contacting the patient’s GP or oncology nurse.

Ulcers and Wounds

Ulceration in chemotherapy patients warrants proactive management with offloading, non-adherent dressings, and infection surveillance. Aggressive debridement is typically avoided during neutropenia or thrombocytopenia due to bleeding and infection risks.

Footwear and Mechanical Strategies

Footwear determines both the distribution of plantar pressure and the magnitude of shear forces; two crucial contributors to chemotherapy-related foot complications. Patients often resort to soft slippers or loose shoes due to pain, but these undermine stability and can worsen neuropathy-related gait disturbances.

Recommended Features

  • Breathable materials to reduce sweating and friction

  • Seamless or minimal-seam interiors

  • Cushioned midsoles (EVA, PU, or hybrid foams)

  • Stable heel counter

  • Wide toe box

  • Moderate rocker sole for painful toe-off in PPE or nail pain

What to Avoid

  • Narrow or rigid footwear

  • High heels

  • Flip-flops

  • Barefoot walking

  • Hard leather interiors

Footwear should be revisited at each appointment, as patients may modify choices based on comfort fluctuations with chemotherapy cycles.

Clinical Red Flags Requiring Urgent Escalation

Certain findings necessitate immediate medical attention:

  • Fever in the presence of any foot lesion

  • Spreading erythema suggestive of cellulitis

  • Pus, abscess, or foul odour

  • Sudden inability to weight-bear

  • Rapidly worsening neuropathic pain

  • New foot drop

  • Suspected deep tissue infection

  • Ulcers in neutropenic patients

Any sign of systemic illness in conjunction with foot lesions should be treated as a potential medical emergency.

Suggested Clinical Workflow in Podiatric Practice

A structured workflow ensures consistent, safe, and proactive care.

Initial Consultation

The first appointment should include comprehensive history, full dermatological and neurological examination, baseline photographs, footwear assessment, and the creation of a risk profile. Patients should be provided with a written self-care guide emphasising daily inspection, moisturising, and early reporting of changes.

Follow-Up Schedule

  • Low-risk patients may be reviewed every 6–8 weeks.

  • Moderate-risk patients benefit from reviews every 4–6 weeks.

  • High-risk patients including those with neuropathy, fissures, PPE, or nail loss, should be seen every 2–4 weeks.

  • Critical-risk patients, such as those with early infection or severe PPE, require weekly monitoring or until stabilised.

Communication with Oncology Teams

Key findings such as worsening PPE, loss of protective sensation, severe nail toxicity, infection, or functional decline should be communicated directly to the oncology unit. Documentation should reference objective findings and, where appropriate, CTCAE grading.

Conclusion

Chemotherapy affects every dimension of foot health: the skin becomes fragile, the nails vulnerable, the nerves sensitive or numb, and gait changes subtly yet significantly. These complications are not mere discomforts, they shape a patient’s mobility, safety, independence, and ultimately their ability to continue life-saving cancer treatment.

By combining dermatological care, neurological understanding, biomechanical management, and vigilant monitoring, podiatrists protect far more than feet. They safeguard the patient’s capacity to move, to function, and to remain on treatment. This expands the podiatrist’s role from ancillary clinician to a vital partner in oncology care.

Cancer therapies may be harsh, but with the right intervention at the right time, the feet need not bear the brunt of collateral damage. The goal is simple but profound: keep patients walking safely, comfortably, and confidently through some of the most challenging months of their lives.

References:

  1. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010 Dec;6(12):657–66.

  2. Loprinzi CL et al. The prevention and management of chemotherapy-induced peripheral neuropathy in survivors and patients: ASCO guideline update. J Clin Oncol. 2020;38(28):3325–48.

  3. Nagore E et al. Hand–foot syndrome: Incidence, impact and management. Am J Clin Dermatol. 2014;15(5):421–31.

  4. Cleeland CS et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592–6.

  5. Freifeld AG et al. Clinical practice guideline for antimicrobial prophylaxis for cancer patients. Clin Infect Dis. 2011;52(4):e56–93.

  6. Kolb NA et al. A systematic review of chemotherapy-related cognitive impairment, neuropathy, and falls. J Geriatr Oncol. 2016;7(2):76–83.

  7. Kawakami Y et al. Skin toxicity induced by chemotherapy agents. J Dermatol. 2011;38(11):1043–51.

  8. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803–12.

  9. Mao M et al. Skin manifestations associated with chemotherapy and targeted therapy in cancer patients. J Drugs Dermatol. 2014;13(11):1385–93.

  10. Miller KK et al. Symptoms and symptom clusters in patients with breast cancer receiving chemotherapy. Eur J Oncol Nurs. 2015;19(1):13–9.

  11. Park SB et al. Chemotherapy-induced peripheral neuropathy: A critical analysis. CA Cancer J Clin. 2013;63(6):419–37.

  12. Argyriou AA et al. A review of oxaliplatin-induced peripheral neuropathy. Cancer Treat Rev. 2008;34(4):368–77.

  13. Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.

  14. Seretny M et al. Incidence, prevalence and predictors of CIPN: Systematic review and meta-analysis. Pain. 2014;155(12):2461–70.

  15. Gordon IO et al. Endothelial injury in chemotherapy. Cancer Chemother Pharmacol. 2006;57(4):349–55.

  16. Minisini AM et al. Taxane-induced nail toxicity: Incidence, clinical presentation and management. Ann Oncol. 2003;14(9):1317–21.

  17. Robert C et al. Management of EGFR inhibitor-related toxicities. Lancet Oncol. 2005;6(12):733–43.

  18. Winters-Stone KM et al. Falls, functioning, and disability in prostate cancer survivors. Support Care Cancer. 2017;25(2):513–20.

  19. Argyriou AA et al. Peripheral neuropathy induced by chemotherapy: A review. Crit Rev Oncol Hematol. 2012;82(1):51–77.

  20. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. 2017.

  21. Di Palma M et al. Clinical impact of PPE in capecitabine-treated patients. Cancer Treat Rev. 2017;53:40–9.

  22. Lodén M. Effectiveness of urea-containing moisturizers. Acta Derm Venereol. 2016;96(1):1–6.

  23. Yap YS et al. Corticosteroids in the management of hand–foot syndrome. Cancer Chemother Pharmacol. 2017;80(6):1103–10.

  24. European Society for Medical Oncology. ESMO Guidelines for PPE management. 2021.

  25. Segaert S, Van Cutsem E. Management of EGFR-inhibitor-induced paronychia. Ann Oncol. 2005;16(1):1815–24.

  26. Saif MW et al. Management of EGFR inhibitor-induced cutaneous toxicity. J Support Oncol. 2007;5(9):455–66.

  27. Smith EM et al. Duloxetine for the treatment of CIPN. JAMA. 2013;309(13):1359–67.

  28. Villanueva A et al. Antifungal therapy in neutropenic patients. Clin Infect Dis. 2002;34(5):730–42.

Simplified complete reading view